Phenotyping Patients With Severe Asthma: Check Those Biomarkers!

Phenotyping Patients With Severe Asthma: Check Those Biomarkers! Posted By:
...

Asthma affected approximately 262 million people globally in 2019, and an estimated 5% to 10% of these people had severe asthma—a chronic lung disease that remains uncontrolled despite maximum use of inhaled corticosteroids and/or other controller medications. In patients with uncontrolled symptoms, stepping up to targeted biologic therapy is the next appropriate approach to care. 

There are now 6 biologic therapies for asthma available. Each of these treatments, when used in appropriate patients, has been shown to reduce exacerbations, hospitalizations, and healthcare utilization; improve symptoms overall and asthma-related quality of life; decrease oral and/or inhaled corticosteroid use; and some agents positively affect lung function by some parameters. However, given the heterogeneity of asthma, it is important to determine the underlying phenotype in those with severe asthma, as this aids healthcare professionals (HCPs) in selecting the most appropriate biologic agents and improving outcomes. In asthma, HCPs can use biomarkers to determine underlying disease phenotypes and predict response and probable success with the various biologic agents available. Phenotyping patients, or checking for biomarkers, is therefore crucial to improve patient outcomes. 

In general, there are 2 major types of asthma: type 2 high inflammation (T2-high) and type 2 low inflammation (T2-low). Currently, there are no commercially useful biomarkers to assess for T2-low asthma. However, for T2-high asthma, there are several biomarkers—blood eosinophils, serum total immunoglobulin E (IgE), fractional exhaled nitric oxide (FeNO), and allergen-specific IgE levels—and biologic agents available for diagnosing and managing severe asthma. These agents’ respective targets and related biomarkers are shown below (Table).

Table. Severe Asthma Biologic Agents and Their Targets, Endotypes, and Biomarkers

Biomarkers are important not only for phenotyping asthma, but also for aiding the accurate diagnosis, disease severity, and exacerbation risk; selection of the proper biologic therapy; and observation of treatment response. Furthermore, many patients have mixed phenotypes; therefore, assessing their biomarker status is an important step to determine how to best proceed with their care. Assessing biomarkers allows for personalized treatment tailored to each patient’s unique presentation. Improving patient outcomes, symptom control, and quality of life are all crucial aspects of chronic disease management. Prompt referral of all patients with severe, uncontrolled, or difficult-to-manage asthma to allergy/immunology or pulmonology specialists is crucial for managing and optimizing treatment outcomes.


Share

Filed under: Allergy/Immunology

Related
A Major Change in Asthma Management – Is This the Beginning of the End for SABAs?

A Major Change in Asthma Management – Is This th ...

The most recent updated Global Initiative for Asthma (GINA) guidelines recommend that short-acting ...

Filed under: Preventive Medicine, Pulmonary Medicine, NPs & PAs, Allergy/Immunology


Continue Reading
Improving Atopic Dermatitis Care

Improving Atopic Dermatitis Care

Facilitating Improvements in Transitions of Care in AD ManagementAtopic dermatitis (AD) is a chronic ...

Filed under: Dermatology, NPs & PAs, Allergy/Immunology


Continue Reading
Trigger Avoidance as a Basic Element in Atopic Dermatitis Management

Trigger Avoidance as a Basic Element in Atopic Der ...

Atopic dermatitis (AD) is a chronic inflammatory disorder affecting millions of pediatric patients ...

Filed under: Dermatology, NPs & PAs, Allergy/Immunology


Continue Reading
Navigating Challenges in the Implementation of Early Peanut Introduction Guidelines

Navigating Challenges in the Implementation of Ear ...

In 2017, the National Institute of Allergy and Infectious Diseases (NIAID) released guidelines advoc ...

Filed under: NPs & PAs, Allergy/Immunology


Continue Reading
JAK Inhibitors for the Management of Atopic Dermatitis

JAK Inhibitors for the Management of Atopic Dermat ...

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease estimated to affect up to ...

Filed under: Allergy/Immunology, Dermatology


Continue Reading
Yes, You Really Can Be "Allergic" to the Cold

Yes, You Really Can Be "Allergic" to the Cold

Cold-induced urticaria is a subtype of chronic inducible urticaria that affects approximately 0.05% ...

Filed under: Allergy/Immunology, Curbside Consultations


Continue Reading